{"id":"bemnifosbuvir-bem","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bemnifosbuvir is a phosphoramidate prodrug of a nucleoside analog that targets the RNA-dependent RNA polymerase (RdRp) of RNA viruses. Upon cellular uptake and metabolic activation, it is incorporated into the viral RNA chain during replication, causing chain termination and preventing viral genome synthesis. This mechanism has broad-spectrum activity against multiple RNA viruses including respiratory viruses.","oneSentence":"Bemnifosbuvir is a nucleoside analog that inhibits viral RNA-dependent RNA polymerase, blocking replication of RNA viruses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:58.226Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (SARS-CoV-2 infection)"},{"name":"Respiratory viral infections"}]},"trialDetails":[{"nctId":"NCT07037277","phase":"PHASE3","title":"C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-06-02","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection","enrollment":880},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT07272889","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":24},{"nctId":"NCT06868264","phase":"PHASE3","title":"C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-07","conditions":"HEPATITIS C VIRUS CHRONIC INFECTION","enrollment":880},{"nctId":"NCT05904470","phase":"PHASE2","title":"A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-05-30","conditions":"Chronic Hepatitis C Virus, Hepatitis C, Chronic, Hepatitis C","enrollment":275},{"nctId":"NCT06911320","phase":"PHASE1","title":"Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function","status":"RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-09","conditions":"Healthy Volunteer Study, Hepatic Impairment, Renal Impairment","enrollment":28},{"nctId":"NCT07007806","phase":"PHASE1","title":"Drug-drug Interaction Study of Omeprazole and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-05-09","conditions":"Healthy Volunteer Study","enrollment":20},{"nctId":"NCT06921941","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Digoxin and Rosuvastatin","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-04-08","conditions":"Healthy Volunteer Study","enrollment":38},{"nctId":"NCT05629962","phase":"PHASE3","title":"SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2022-11-25","conditions":"Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2 Infection), COVID-19","enrollment":2285},{"nctId":"NCT06204679","phase":"PHASE1","title":"Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-12-14","conditions":"Healthy Volunteer Study","enrollment":42},{"nctId":"NCT05724693","phase":"PHASE1","title":"Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-01-30","conditions":"Healthy Volunteer, Hepatic Impairment","enrollment":39},{"nctId":"NCT06356194","phase":"PHASE1","title":"Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2024-04-15","conditions":"Healthy Volunteer Study","enrollment":28},{"nctId":"NCT05905497","phase":"PHASE1","title":"The Study of Bemnifosbuvir in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-04-26","conditions":"Healthy Volunteer Study","enrollment":14},{"nctId":"NCT05905484","phase":"PHASE1","title":"Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-04-25","conditions":"Healthy Volunteer Study","enrollment":35},{"nctId":"NCT05731843","phase":"PHASE1","title":"Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir","status":"COMPLETED","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2023-01-30","conditions":"Healthy Volunteer Study","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AT-527"],"phase":"phase_3","status":"active","brandName":"Bemnifosbuvir (BEM)","genericName":"Bemnifosbuvir (BEM)","companyName":"Atea Pharmaceuticals, Inc.","companyId":"atea-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bemnifosbuvir (BEM) is a small molecule with an unknown mechanism of action, as its specific mechanism is not provided in the given facts. It is being studied in a Phase 1 clinical trial to evaluate its interaction with buprenorphine/naloxone or methadone in healthy volunteers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}